Novartis' PI3Kα inhibitor meets in Phase III for breast cancer
Novartis AG (NYSE:NVS; SIX:NOVN) said alpelisib (BYL719) met the primary endpoint in the Phase III SOLAR-1 trial to treat advanced breast cancer in previously treated patients that harbor the phosphoinositide 3-kinase (PI3K) catalytic subunit α polypeptide (PI3KCA; p110α) mutation. The pharma did not report detailed data but said it will discuss them with regulators worldwide. Alpelisib is a PI3Kα inhibitor.
The announcement comes two months after Roche (SIX:ROG; OTCQX:RHHBY) threw in the towel on its own PI3Kα inhibitor, taselisib (RG7604), in metastatic breast cancer after the compound showed lackluster efficacy data and considerable side effects in a Phase III trial...